Filing Details
- Accession Number:
- 0001765581-23-000036
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-10 18:10:38
- Reporting Period:
- 2023-03-08
- Accepted Time:
- 2023-03-10 18:10:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1232524 | Jazz Pharmaceuticals Plc | JAZZ | Pharmaceutical Preparations (2834) | 981032470 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1758790 | Kim Sablich | 5Th Fl, Waterloo Exchange Waterloo Rd Dublin 4 L2 | Evp, Gm Of U.s., Commercial Ma | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Disposition | 2023-03-08 | 1,752 | $139.42 | 31,821 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2023-03-08 | 1,261 | $140.19 | 30,560 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.95 to $139.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $139.97 to $140.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Billionaire Hedge Funds
